The selective cyclooxygenase-2 (COX2) inhibitor celecoxib appears to be safer for mother and fetus than the nonselective COX inhibitor indomethacin when used to treat preterm delivery, according to results of a prospective, placebo-controlled study.
The expression and activity of amniotic COX-2, but not COX-1, increases appreciably in women with term labor, idiopathic preterm labor, or preterm labor associated with uterine overdistention, explain Dr. Catherine S. Stika, of Northwestern University in Chicago, and colleagues.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!